AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 259: H1152-H1160, 1990;
0363-6135/90 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Minkes, R. K.
Right arrow Articles by Kadowitz, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Minkes, R. K.
Right arrow Articles by Kadowitz, P. J.

AJP - Heart and Circulatory Physiology, Vol 259, Issue 4 1152-H1160, Copyright © 1990 by American Physiological Society


ARTICLES

Cardiovascular responses to vasoactive intestinal contractor, a novel endothelin-like peptide

R. K. Minkes, T. R. Higuera, G. F. Rogers, E. A. Sheldon, M. A. Langston and P. J. Kadowitz
Department of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana 70112.

Cardiovascular and pulmonary responses to vasoactive intestinal contractor (VIC), an endothelin (ET)-like peptide from the murine gastrointestinal tract, were investigated in the cat. VIC (0.1-1.0 nmol/kg iv) decreased or elicited biphasic changes in arterial pressure (AP) and increased central venous pressure, cardiac output, pulmonary arterial pressure, and left atrial pressure. VIC produced biphasic changes in systemic vascular resistance (SVR) and pulmonary vascular resistance (PVR). VIC increased heart rate (HR) and, at the 1 nmol/kg dose, a secondary decrease was observed. Hexamethonium blocked the changes in HR in response to VIC, whereas the ganglionic blocker, meclofenamate, or glybenclamide had no effect on changes in AP, SVR, and PVR elicited by the peptide. VIC caused small changes in right ventricular contractile force and increased distal aortic and carotid artery blood flow at all doses, with secondary decreases at the higher doses. VIC decreased superior mesenteric artery flow and decreased renal blood flow at the 1 nmol/kg dose. The changes in AP in response to VIC, ET-1, and ET-2 were similar, whereas those elicited by ET-3 and sarafotoxin 6b were similar. The present data show that VIC can produce both vasodilation and vasoconstriction in the systemic vascular bed and biphasic changes in PVR in the cat. These data show that VIC can produce complex cardiovascular responses similar to those elicited by the ET peptides and that these responses are largely independent of autonomic reflexes, release of cyclooxygenase products, and activation of ATP-regulated potassium channels. We conclude that VIC may act as an ET-like peptide.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online